COMMUNIQUÉS West-GlobeNewswire

NewBiologix Presents New Data at ASGCT on the Effective Manufacturing of rAAV-based therapeutics
13/05/2025
LAUSANNE, Switzerland, May 13, 2025 (GLOBE NEWSWIRE) -- NewBiologix, a next-generation biotechnology company pioneering the future of recombinant adeno-associated virus (rAAV) production through a unique DNA-based [...]
Arbor Biotechnologies to Present Preclinical Data for ABO-101 in PH1 at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
13/05/2025
– Data from oral presentation supported ABO-101 IND and CTA approval for clinical assessment in primary hyperoxaluria type 1 (PH1) in the Phase 1/2 redePHine study in US and UK ( NCT06839235 ) – Preclinical data [...]
New Retrospective Study Reports Significantly Reduced Post-Operative GERD Rates with the Titan SGS™ Stapler from Teleflex Compared with Multi-Fire Staplers in Sleeve Gastrectomy
13/05/2025
Data also demonstrate significantly lower rates of postoperative reflux and decreased incidence of de novo gastroesophageal reflux disease (GERD) without affecting total weight loss at 1-year*, and shorter average [...]
Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments
13/05/2025
Reported Net Product Revenues of $20.9 million for the first quarter of 2025, a year-over-year increase of approximately 8% National Comprehensive Cancer Network ® (NCCN ® ) Clinical Practice Guidelines in Oncology for [...]
Immatics Announces First Quarter 2025 Financial Results and Business Update
13/05/2025
IMA203 PRAME Cell Therapy: Randomized-controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing and expected to complete enrollment in 2026 IMA203 PRAME Cell Therapy: Phase 1b clinical trial [...]
GenVivo Highlights GEN2 Phase 1 Data and GEN-1013 Preclinical Data at the 2025 American Society of Gene + Cell Therapy (ASGCT) Annual Meeting
13/05/2025
GEN2 is well tolerated with minimal toxicity and signs of pharmacodynamic activity in an ongoing Phase 1 dose escalation and expansion trial. GEN-1013 was studied in aggressive murine cancer models using both IV and IT [...]
Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity
13/05/2025
• This model demonstrates that central inhibition of CB1 is not required for weight loss • Anti-CB1 inhibiting antibody, nimacimab, showed greatest peripheral restriction compared with monlunabant and rimonabant, small [...]
Algernon to Acquire NoBrainer Imaging Centers, Inc. - Plans to Establish Alzheimer’s Diagnostic and Treatment Medical Clinics Featuring New PET Scan Technology
13/05/2025
First Clinic Targeted to Open Q4, 2025 in the U.S. VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a [...]
Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone
13/05/2025
Previous term loan facility retired NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) [...]
Microbix & Aurevia Introduce Novel EQA Scheme
13/05/2025
Pilot Program for Qualifying Clinical Labs to Diagnose Bacterial Vaginosis MISSISSAUGA, Ontario and HELSINKI, Finland, May 13, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix® ), a [...]
Legend Biotech Reports First Quarter 2025 Results and Recent Highlights
13/05/2025
CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $369 million Over 6,000 patients treated to date Initiated CARVYKTI ® clinical production at the Tech Lane facility Received positive [...]
NMD Pharma to present compelling preclinical data highlighting the potential of ClC-1 ion channel inhibition to improve disease symptoms and progression in MuSK myasthenia gravis at the MGFA International Conference on Myasthenia and Relate
13/05/2025
NMD Pharma to present compelling preclinical data highlighting the potential of ClC-1 ion channel inhibition to improve disease symptoms and progression in MuSK myasthenia gravis at the MGFA International Conference on [...]
IBA lance CASSY®, un nouveau module compact de radiochimie pour améliorer l'efficacité de la production de radiopharmaceutiques
13/05/2025
Louvain-la-Neuve, Belgique, le 13 mai 2025 – IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélération de particules et le principal fournisseur de solutions de production de [...]
IBA launches CASSY®, a new compact radiochemistry module to enhance efficiency in radiopharmaceuticals production
13/05/2025
Louvain-La-Neuve, Belgium, 13 May 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the leading provider of radiopharmaceutical production solutions, today [...]
Kuros Biosciences to share latest MagnetOs™ market impact and strategic priorities at Capital Market Day in Zürich
13/05/2025
Kuros Biosciences to share latest MagnetOs™ market impact and strategic priorities at Capital Markets Day in Zürich Schlieren (Zürich), Switzerland, May 13, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader [...]
Ten-year APHINITY data show Roche’s Perjeta-based regimen reduced the risk of death by 17% in people with HER2-positive early-stage breast cancer
13/05/2025
Long term follow-up in this curative setting demonstrated clinically meaningful survival benefit when adding adjuvant Perjeta® (pertuzumab) to Herceptin® (trastuzumab) and chemotherapy 1 21% reduction in the risk of [...]
Vivoryon Therapeutics N.V. to Hold its 2025 Annual General Meeting on June 24, 2025
13/05/2025
Vivoryon Therapeutics N.V. to Hold its 2025 Annual General Meeting on June 24, 2025 Halle (Saale) / Munich, Germany, May 13, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a [...]
Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes
13/05/2025
Galapagos to re-evaluate the implementation of the previously announced separation following regulatory and market developments Galapagos to explore all strategic alternatives for its existing businesses, including cell [...]
First patients dosed in final cohort of Phase 1b clinical trial of HER-096 for Parkinson’s disease
13/05/2025
Herantis Pharma Plc – Press release First patients dosed in final cohort of Phase 1b clinical trial of HER-096 for Parkinson’s disease HER-096 is a first-in-class agent in development for the treatment of Parkinson’s [...]

Pages